Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.23
ANIP's Cash-to-Debt is ranked lower than
93% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. ANIP: 0.23 )
Ranked among companies with meaningful Cash-to-Debt only.
ANIP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: No Debt Max: No Debt
Current: 0.23
Equity-to-Asset 0.53
ANIP's Equity-to-Asset is ranked lower than
64% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ANIP: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
ANIP' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.11  Med: 0.74 Max: 0.95
Current: 0.53
-3.11
0.95
Interest Coverage 1.77
ANIP's Interest Coverage is ranked lower than
97% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANIP: 1.77 )
Ranked among companies with meaningful Interest Coverage only.
ANIP' s Interest Coverage Range Over the Past 10 Years
Min: 1.77  Med: 14.2 Max: No Debt
Current: 1.77
Piotroski F-Score: 5
Altman Z-Score: 2.94
Beneish M-Score: -1.36
WACC vs ROIC
21.99%
4.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 15.61
ANIP's Operating Margin % is ranked higher than
84% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. ANIP: 15.61 )
Ranked among companies with meaningful Operating Margin % only.
ANIP' s Operating Margin % Range Over the Past 10 Years
Min: -11707.36  Med: -238.32 Max: 42.84
Current: 15.61
-11707.36
42.84
Net Margin % 3.06
ANIP's Net Margin % is ranked higher than
73% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. ANIP: 3.06 )
Ranked among companies with meaningful Net Margin % only.
ANIP' s Net Margin % Range Over the Past 10 Years
Min: -11864.14  Med: -234.13 Max: 51.36
Current: 3.06
-11864.14
51.36
ROE % 2.38
ANIP's ROE % is ranked higher than
78% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. ANIP: 2.38 )
Ranked among companies with meaningful ROE % only.
ANIP' s ROE % Range Over the Past 10 Years
Min: -320.53  Med: -55.88 Max: 31.63
Current: 2.38
-320.53
31.63
ROA % 1.29
ANIP's ROA % is ranked higher than
79% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ANIP: 1.29 )
Ranked among companies with meaningful ROA % only.
ANIP' s ROA % Range Over the Past 10 Years
Min: -175.65  Med: -16.13 Max: 18.91
Current: 1.29
-175.65
18.91
ROC (Joel Greenblatt) % 44.32
ANIP's ROC (Joel Greenblatt) % is ranked higher than
91% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. ANIP: 44.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ANIP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6803.87  Med: -133.17 Max: 127.69
Current: 44.32
-6803.87
127.69
3-Year Revenue Growth Rate 23.30
ANIP's 3-Year Revenue Growth Rate is ranked higher than
74% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. ANIP: 23.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ANIP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 24 Max: 385
Current: 23.3
0
385
3-Year EBITDA Growth Rate 110.00
ANIP's 3-Year EBITDA Growth Rate is ranked higher than
98% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. ANIP: 110.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ANIP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -22  Med: 11.5 Max: 267.5
Current: 110
-22
267.5
GuruFocus has detected 3 Warning Signs with ANI Pharmaceuticals Inc $ANIP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ANIP's 10-Y Financials

Financials (Next Earnings Date: 2017-06-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ANIP Guru Trades in Q1 2016

Joel Greenblatt 11,688 sh (New)
Paul Tudor Jones 12,431 sh (+8.56%)
Third Avenue Management 50,053 sh (unchged)
» More
Q2 2016

ANIP Guru Trades in Q2 2016

Jim Simons 73,900 sh (New)
Third Avenue Management 50,053 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt 7,324 sh (-37.34%)
» More
Q3 2016

ANIP Guru Trades in Q3 2016

Paul Tudor Jones 6,500 sh (New)
Jim Simons 190,900 sh (+158.32%)
Third Avenue Management 50,053 sh (unchged)
Joel Greenblatt 4,763 sh (-34.97%)
» More
Q4 2016

ANIP Guru Trades in Q4 2016

Jim Simons 232,700 sh (+21.90%)
Third Avenue Management 49,933 sh (-0.24%)
Joel Greenblatt 4,137 sh (-13.14%)
Paul Tudor Jones 4,600 sh (-29.23%)
» More
» Details

Insider Trades

Latest Guru Trades with ANIP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:RGNX, NAS:SPPI, NAS:CYTK, NAS:ACHN, NAS:ANAB, NAS:OMER, NAS:AMRI, NAS:RARX, NAS:RVNC, NAS:RETA, OTCPK:SPHDF, NAS:ENTA, NAS:NLNK, NAS:NTLA, NAS:WVE, NAS:PACB, NAS:ATRA, NAS:KERX, NAS:MYOK, NAS:CARA » details
ANI Pharmaceuticals Inc is a specialty pharmaceutical company. The Company, together with its subsidiary develops, manufactures and markets branded and generic prescription pharmaceuticals products.

ANI Pharmaceuticals Inc was organized as a Delaware corporation in April 2001. The Company, together with its subsidiary is a specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals products. Its targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. It has two pharmaceutical manufacturing facilities located in Baudette, Minnesota, which are capable of producing oral solid dose products, as well as liquids and topicals, narcotics, and potent products that must be manufactured in a fully-contained environment. It also performs contract manufacturing for other pharmaceutical companies. In addition to laboratories that support all of the requirements of raw materials, finished products, and stability testing, the Company has a 1,000 square foot pilot laboratory offering liquid, suspension and solid dose development capabilities. This pilot laboratory offers a range of analytical capabilities including method development, validation and de-formulation, and is licensed by the Drug Enforcement Administration. Its branded products are Cortenema, Reglan Tablets; and its generic products are Esterified Estrogen with Methyltestosterone Tablets, Fluvoxamine Maleate Tablets, Hydrocortisone Enema, Metoclopramide Syrup and Opium Tincture. Its Esterified Estrogen with Methyltestosterone product is used to treat moderate to severe vasomotor symptoms of menopause, such as hot flashes and heart palpations that are not improved by estrogen medications alone. Its Fluvoxamine Maleate product is used to treat obsessions and compulsions in patients with obsessive-compulsive disorder. Hydrocortisone Enema and its branded equivalent, Cortenema are used for the treatment of ulcerative colitis, especially distal forms, including ulcerative proctitis, ulcerative proctosigmoiditis, and left-sided ulcerative colitis. Its Metoclopramide syrup and its branded equivalent Reglan, in tablet form, are prescribed for periods of four to twelve weeks for heartburn symptoms with gastroesophageal reflux disease when certain other treatments do not work. Its Opium Tincture is used to treat severe diarrhea by slowing the movement of the intestines and decreasing the number and frequency of bowel movements. It owns the trademark names for each of its branded products, Cortenema and Reglan. Its products are sold by four retail pharmacy chains; Walgreens, CVS, RiteAid and Wal-Mart, and are included in the source programs of four national wholesalers; Cardinal, McKesson, AmerisourceBergen and Morris Dickson, which are also wholesale customers of the Company. The Company competes all of its drugs with Creekwood Pharmaceuticals, Endo Pharmaceuticals, Glenmark Pharmaceuticals, Novartis AG, Watson Pharmaceuticals, and Teva Pharmaceuticals USA., Lannett, and Roxane Laboratories

Ratios

vs
industry
vs
history
PE Ratio 145.14
ANIP's PE Ratio is ranked lower than
92% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. ANIP: 145.14 )
Ranked among companies with meaningful PE Ratio only.
ANIP' s PE Ratio Range Over the Past 10 Years
Min: 12.74  Med: 26.39 Max: 191.94
Current: 145.14
12.74
191.94
Forward PE Ratio 27.17
ANIP's Forward PE Ratio is ranked lower than
61% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 20.12 vs. ANIP: 27.17 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 145.14
ANIP's PE Ratio without NRI is ranked lower than
91% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 28.10 vs. ANIP: 145.14 )
Ranked among companies with meaningful PE Ratio without NRI only.
ANIP' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.74  Med: 26.39 Max: 191.94
Current: 145.14
12.74
191.94
PB Ratio 3.38
ANIP's PB Ratio is ranked higher than
56% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ANIP: 3.38 )
Ranked among companies with meaningful PB Ratio only.
ANIP' s PB Ratio Range Over the Past 10 Years
Min: 0.83  Med: 4.51 Max: 33.97
Current: 3.38
0.83
33.97
PS Ratio 4.45
ANIP's PS Ratio is ranked higher than
76% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. ANIP: 4.45 )
Ranked among companies with meaningful PS Ratio only.
ANIP' s PS Ratio Range Over the Past 10 Years
Min: 0.82  Med: 11.51 Max: 824.15
Current: 4.45
0.82
824.15
Price-to-Operating-Cash-Flow 20.73
ANIP's Price-to-Operating-Cash-Flow is ranked higher than
52% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 20.83 vs. ANIP: 20.73 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ANIP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.63  Med: 34.48 Max: 429.07
Current: 20.73
13.63
429.07
EV-to-EBIT 33.14
ANIP's EV-to-EBIT is ranked lower than
69% of the 320 Companies
in the Global Biotechnology industry.

( Industry Median: 21.73 vs. ANIP: 33.14 )
Ranked among companies with meaningful EV-to-EBIT only.
ANIP' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.7  Med: -0.9 Max: 168
Current: 33.14
-33.7
168
EV-to-EBITDA 15.72
ANIP's EV-to-EBITDA is ranked higher than
55% of the 355 Companies
in the Global Biotechnology industry.

( Industry Median: 16.79 vs. ANIP: 15.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANIP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.4  Med: -0.7 Max: 72.7
Current: 15.72
-43.4
72.7
Shiller PE Ratio 0.14
ANIP's Shiller PE Ratio is ranked higher than
98% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 52.28 vs. ANIP: 0.14 )
Ranked among companies with meaningful Shiller PE Ratio only.
ANIP' s Shiller PE Ratio Range Over the Past 10 Years
Min: 0.02  Med: 0.12 Max: 0.21
Current: 0.14
0.02
0.21
Current Ratio 3.22
ANIP's Current Ratio is ranked lower than
58% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ANIP: 3.22 )
Ranked among companies with meaningful Current Ratio only.
ANIP' s Current Ratio Range Over the Past 10 Years
Min: 1.11  Med: 5.16 Max: 20.45
Current: 3.22
1.11
20.45
Quick Ratio 2.40
ANIP's Quick Ratio is ranked lower than
64% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ANIP: 2.40 )
Ranked among companies with meaningful Quick Ratio only.
ANIP' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 5.16 Max: 20.45
Current: 2.4
0.75
20.45
Days Inventory 159.84
ANIP's Days Inventory is ranked lower than
59% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. ANIP: 159.84 )
Ranked among companies with meaningful Days Inventory only.
ANIP' s Days Inventory Range Over the Past 10 Years
Min: 55.94  Med: 148.04 Max: 300.6
Current: 159.84
55.94
300.6
Days Sales Outstanding 130.24
ANIP's Days Sales Outstanding is ranked lower than
82% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. ANIP: 130.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANIP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.11  Med: 101.11 Max: 151.83
Current: 130.24
11.11
151.83
Days Payable 25.36
ANIP's Days Payable is ranked lower than
76% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. ANIP: 25.36 )
Ranked among companies with meaningful Days Payable only.
ANIP' s Days Payable Range Over the Past 10 Years
Min: 25.36  Med: 69.4 Max: 2968.67
Current: 25.36
25.36
2968.67

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.40
ANIP's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. ANIP: -6.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ANIP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -65.4  Med: -34.25 Max: -6.4
Current: -6.4
-65.4
-6.4

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.39
ANIP's Price-to-Median-PS-Value is ranked higher than
87% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. ANIP: 0.39 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ANIP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 3.03 Max: 103.29
Current: 0.39
0.18
103.29
Earnings Yield (Greenblatt) % 3.00
ANIP's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. ANIP: 3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ANIP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.6  Med: 3.8 Max: 8709
Current: 3
0.6
8709

More Statistics

Revenue (TTM) (Mil) $128.6
EPS (TTM) $ 0.34
Beta3.09
Short Percentage of Float11.07%
52-Week Range $30.60 - 70.92
Shares Outstanding (Mil)11.60

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 185 207
EPS ($) 1.80 2.38
EPS without NRI ($) 1.80 2.38
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ANIP

Headlines

Articles On GuruFocus.com
Context Capital Management's Top Sales in Q2 2015 Jul 17 2015 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly CEO Buys Highlight: MSCI, WINA, BPAX Jan 22 2011 
Biosante Pharmaceuticals Inc. (BPAX) CFO Philip B Donenberg buys 1,000 Shares Jan 21 2011 
Biosante Pharmaceuticals Inc. (BPAX) CEO Stephen M Simes buys 5,000 Shares Jan 19 2011 
Biosante Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Biosante Pharmaceuticals Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
ANI PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 14 2017
Moving Average Crossover Alert: ANI Pharmaceuticals (ANIP) Mar 13 2017
ANI PHARMACEUTICALS INC Financials Mar 08 2017
ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
ANI reports 4Q loss Mar 02 2017
ANI reports 4Q loss Mar 02 2017
ANI PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 02 2017
ANI Pharmaceuticals Reports Full Year 2016 Results and Fourth Quarter Results and Provides 2017... Mar 02 2017
Q4 2016 ANI Pharmaceuticals Inc Earnings Release - Before Market Open Mar 02 2017
ANI PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion... Feb 24 2017
ANI Pharmaceuticals Acquires Inderal® XL and InnoPran XL® Feb 24 2017
ANI Pharma downgraded by ROTH Capital Feb 22 2017
ANI PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 16 2017
ANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2016 Financial... Feb 16 2017
ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US :... Feb 01 2017
ANI Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ANIP) : January 19, 2017 Jan 19 2017
ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ANIP-US : January... Jan 18 2017
ANI Announces Appointment of Karen Quinn Ph.D as Vice President Corticotropin Regulatory Affairs Jan 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)